Evidence map›Paper›PMID 35455424›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Ahmed E Altyar, Ans Munir, Saiqa Ishtiaq, Muhammad Rizwan, Khizar Abbas, Osama Kensara, Sameh S Elhady, Waleed Y Rizg, Fadia S Youssef, Mohamed L Ashour

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Potential Antidiabetic Effects ofCurrent therapeutic research, clinical and experimental · 2026
    Article
  3. Evaluation of the protective role ofOpen veterinary journal · 2025
    Article
  4. Article
  5. Correction: Altyar et al.Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  6. Article
  7. Article
  8. Review
  9. Metabolic Profiling ofMetabolites · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

Ahmed E AltyarDepartment of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, P.O. Box 80260, Jeddah 21589, Saudi Arabia.ORCID 0000-0001-6210-3628
Ans MunirDepartment of Pharmacognosy, College of Pharmacy, University of the Punjab, Lahore 54000, Pakistan.
Saiqa IshtiaqDepartment of Pharmacognosy, College of Pharmacy, University of the Punjab, Lahore 54000, Pakistan.
Muhammad RizwanDepartment of Pathology, Lahore Medical and Dental College, University of Health Sciences, Lahore 54600, Pakistan.
Khizar AbbasDepartment of Pharmacognosy, Faculty of Pharmacy, Bahauddin Zakariya University, Multan 60800, Pakistan.
Osama KensaraDepartment of Clinical Nutrition, Faculty of Applied Medical Sciences, Umm Al-Qura University, P.O. Box 7067, Makkah 21955, Saudi Arabia.
Sameh S ElhadyDepartment of Natural Products, Faculty of Pharmacy, King Abdulaziz University, P.O. Box 80260, Jeddah 21589, Saudi Arabia.ORCID 0000-0003-3799-0581
Waleed Y RizgDepartment of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, P.O. Box 80260, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-3088-4084
Fadia S YoussefDepartment of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, Abbasia, Cairo 11566, Egypt.ORCID 0000-0002-5871-2639
Mohamed L AshourDepartment of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, Abbasia, Cairo 11566, Egypt.ORCID 0000-0002-9270-6267
King Abdulaziz University · SAAin Shams University · EGUniversity of the Punjab · PKBahauddin Zakariya University · PKUmm al-Qura University · SAUniversity of Health Sciences Lahore · PK

Funding

The Deanship of Scientific Research (DSR) at King Abdulaziz University, Jeddah, Saudi Arabia G-68-166-38
6 · The paper itself

Abstract

Malva parviflora L., Little mallow, has been traditionally used as an alternative food source. It acts as a medicinal herb containing a potential source of mucilage thus herein; we aimed to assess the toxicity, anti-inflammatory, antitussive and gastro-protective actions of M. parviflora mucilage extracted from its leaves (MLM) and fruit (MFM). Toxicity studies were investigated by in vitro hemolytic assay whereas acute anti-inflammatory and antitussive activities were assessed by carrageenan-induced paw edema and sulphur dioxide induced cough model in rats, respectively. Gastro-protective effects were studied using ethanol induced acute and chronic gastric ulcer rat models. Their metabolic profiles were determined using gas chromatography. The results revealed that MLM and MFM were non-toxic towards human erythrocytes and their lethal doses were found to be greater than 5 g/kg. Pretreatment with MLM (500 mg/kg) and MFM (500 mg/kg) significantly reduced the carrageenan-induced paw thickness (p < 0.001). Maximum edema inhibition (%) was observed at 4 h in diclofenac sodium (39.31%) followed by MLM (27.35%) and MFM (15.68%). Animals pretreated with MLM (500 mg/kg) significantly lower the cough frequency in SO2 gas induced cough models in contrast to control. Moreover, MLM at doses of 250 and 500 mg/kg reduced the ethanol induced gastric mucosal injuries in acute gastric ulcer models presenting ulcer inhibition of 23.04 and 38.74%, respectively. The chronic gastric ulcer model MFM (500 mg/kg) demonstrated a remarkable gastro-protective effect showing 63.52% ulcer inhibition and results were closely related to standard drug sucralfate. In both models, MLM and MFM decreased gastric juice volume and total acidity in addition to an increased gastric juice pH and gastric mucous content justifying an anti-secretary role of this mucilage that was further confirmed by histopathological examination. Meanwhile, GC analyses of the mucilage revealed their richness with natural as well as acidic monosaccharides. It is concluded that MLM and MFM can be used therapeutically for the management of inflammation, cough and gastric ulcer.

Indexed as

anti-inflammatoryantitussivecytoprotectiongastric ulcerM. parvifloramucilage

Identifiers

PMID35455424
PMCPMC9030788
OpenAlexW4221029297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.